Predicting Failure of Active Surveillance in Desmoid-Type Fibromatosis Using Radiomics: An International Multi-center Cohort Study

Read full text
Authors: Stefanie N. Hakkesteegt, Douwe J. Spaanderman, Chiara Colombo, Anne‐Rose W. Schut, Andrea Vanzulli, Francesco Barretta, C. Morosi, Marco Fiore, Peter Ferguson, Harini Suraweera, Anthony M. Griffin, Lawrence M. White
+25 more Joel Shapiro, Danchen Ge, Dirk Jan Grünhagen, Geert J.L.H. van Leenders, David Hanff, Jacob J. Visser, Wiro J. Niessen, Stefan Klein, L. Been, M. Bemelmans, J. Bonenkamp, S. Dijkstra, F. van Coevorden, S.N. Hakkesteegt, S. Sleijfer, M. Timbergen, D. van Broekhoven, T. van Dalen, R. van Ginkel, W. van Houdt, J. van der Hage, Rebecca A. Gladdy, Alessandro Gronchi, Cornelis Verhoef, Martijn P. A. Starmans
Cited by: 1
References: 22

Abstract

BACKGROUND: Active surveillance (AS) is the first-line approach for desmoid-type fibromatosis (DTF). However, 30 % of patients require active treatment. Identifying these patients will help upfront to define a personalized treatment approach. This study assessed whether radiomics can predict AS failure in patients with DTF. METHODS: This multicenter study included data from the Netherlands (NL), Italy (ITA), and Canada (CAN). The study included patients with extra-abdominal DTF initially managed with AS and baseline MRI. Tumors were segmented using a minimally interactive deep-learning method, and radiomics features were extracted from T1-weighted (T1W) and T2-weighted (T2W) MRI scans. Prediction models to predict AS failure versus no failure were created using various machine-learning approaches. Both an internal cross-validation using all available data and an external leave-one-country-out cross-validation were used to assess model performance. RESULTS: The cohort included 200 patients (72 NL, 62 ITA, 66 CAN), with AS failing for 26 % of the patients. Internal validation of the T1W+T2W imaging model resulted in an overall area under the curve (AUC) of 0.69 (95 % confidence interval [CI] 0.60-0.79). External validation resulted in an AUC of 0.58 (95 % CI 0.42-0.74) in the Dutch cohort, 0.76 (95 % CI 0.60-0.91) in the Italian cohort, and 0.77 (95 % CI 0.65-0.89) in the Canadian cohort. Adding clinical features did not improve the models' performance. CONCLUSIONS: Predicting AS failure with radiomics showed reasonable performance and generalized well to the Italian and Canadian cohorts. Pending improvements to the model or patient selection, the authors' model shows potential to better identify which DTF patients will benefit from AS and which will not.

Fields of Study & Subjects

Soft tissue tumor case studies Soft tissue tumors and treatment Sarcoma Diagnosis and Treatment

Publication details

Journal / source
Annals of Surgical Oncology
Publisher
Springer Science and Business Media LLC
Volume
33
Issue
9
Pages
8591–8600
Publication date
11 June 2026
Language
EN